These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cost-effectiveness of ventricular assist device therapy as a bridge to transplantation compared with nonbridged cardiac recipients. Alba AC; Alba LF; Delgado DH; Rao V; Ross HJ; Goeree R Circulation; 2013 Jun; 127(24):2424-35. PubMed ID: 23697907 [TBL] [Abstract][Full Text] [Related]
5. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy. John R; Kamdar F; Liao K; Colvin-Adams M; Boyle A; Joyce L Ann Thorac Surg; 2008 Oct; 86(4):1227-34; discussion 1234-5. PubMed ID: 18805167 [TBL] [Abstract][Full Text] [Related]
6. The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation. Clegg AJ; Scott DA; Loveman E; Colquitt J; Hutchinson J; Royle P; Bryant J Health Technol Assess; 2005 Nov; 9(45):1-132, iii-iv. PubMed ID: 16303098 [TBL] [Abstract][Full Text] [Related]
7. Implantable ventricular assist devices: is it time to introduce them in Canada? McGregor M Can J Cardiol; 2000 May; 16(5):629-40. PubMed ID: 10833542 [TBL] [Abstract][Full Text] [Related]
8. Costs associated with ventricular assist device use in children. Mahle WT; Ianucci G; Vincent RN; Kanter KR Ann Thorac Surg; 2008 Nov; 86(5):1592-7. PubMed ID: 19049755 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of left ventricular-assist devices in end-stage heart failure. Hutchinson J; Scott DA; Clegg AJ; Loveman E; Royle P; Bryant J; Colquitt JL Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):175-85. PubMed ID: 18248272 [TBL] [Abstract][Full Text] [Related]
10. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403 [TBL] [Abstract][Full Text] [Related]
11. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure. Long EF; Swain GW; Mangi AA Circ Heart Fail; 2014 May; 7(3):470-8. PubMed ID: 24563450 [TBL] [Abstract][Full Text] [Related]
12. [Economic impact of cardiac resynchronization therapy in patients with heart failure. Available evidence and evaluation of the CRT-Eucomed model for analysis of cost-effectiveness]. Fattore G; Landolina M; Bontempi L; Cacciatore G; Curnis A; Gulizia M; Padeletti L; Mazzei L; Tavazzi L; Ital Heart J Suppl; 2005 Dec; 6(12):796-803. PubMed ID: 16444923 [TBL] [Abstract][Full Text] [Related]
13. Improving outcomes with long-term "destination" therapy using left ventricular assist devices. Long JW; Healy AH; Rasmusson BY; Cowley CG; Nelson KE; Kfoury AG; Clayson SE; Reid BB; Moore SA; Blank DU; Renlund DG J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1353-60; discussion 1360-1. PubMed ID: 18544385 [TBL] [Abstract][Full Text] [Related]
14. [The failing heart is helped by a mechanical pump. Prolonged survival and better quality of life in the first randomized trial]. Bergh CH; Swedberg K Lakartidningen; 2002 May; 99(22):2486-8. PubMed ID: 12092046 [No Abstract] [Full Text] [Related]
15. Cost-effectiveness of the implantable HeartMate II left ventricular assist device for patients awaiting heart transplantation. Moreno SG; Novielli N; Cooper NJ J Heart Lung Transplant; 2012 May; 31(5):450-8. PubMed ID: 22115674 [TBL] [Abstract][Full Text] [Related]
16. Longitudinal change in quality of life and impact on survival after left ventricular assist device implantation. Grady KL; Meyer PM; Dressler D; Mattea A; Chillcott S; Loo A; White-Williams C; Todd B; Ormaza S; Kaan A; Costanzo MR; Piccione W Ann Thorac Surg; 2004 Apr; 77(4):1321-7. PubMed ID: 15063260 [TBL] [Abstract][Full Text] [Related]
17. Left ventricular assist device as destination therapy: application of the payment-by-results approach for the device reimbursement. Messori A; Trippoli S; Bonacchi M; Sani G J Thorac Cardiovasc Surg; 2009 Aug; 138(2):480-5. PubMed ID: 19619799 [TBL] [Abstract][Full Text] [Related]
18. Developments in mechanical support as a bridge to cardiac transplant. Hendry P Can J Cardiol; 2004 Mar; 20(4):443-6. PubMed ID: 15057321 [TBL] [Abstract][Full Text] [Related]
19. Improved durability of the HeartMate XVE left ventricular assist device provides safe mechanical support up to 1 year but is associated with high risk of device failure in the second year. Martin J; Friesewinkel O; Benk C; Sorg S; Schultz S; Beyersdorf F J Heart Lung Transplant; 2006 Apr; 25(4):384-90. PubMed ID: 16563965 [TBL] [Abstract][Full Text] [Related]
20. Clinical experience with sternotomy versus subcostal approach for exchange of the HeartMate XVE to the HeartMate II ventricular assist device. Gregoric ID; Bruckner BA; Jacob L; Kar B; Cohn WE; La Francesca S; Frazier OH Ann Thorac Surg; 2008 May; 85(5):1646-9. PubMed ID: 18442556 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]